• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

EntreMed

edit

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.

Recent Milestones

edit

• 
  EntreMed — Kleiner Perkins to Join $10.7M Financing for Publicly Held Biotech Co. EntreMed (3/1/13)
  Posted 3/1/13 at 6:23pm via dowjones.com
• 
  EntreMed received $10M in Venture Round funding. (1/23/12)
  Posted 1/23/12 at 8:32pm via entremed.com

Videos

Screenshots

edit

Sources

1. EntreMed Secures $10 Million Strategic Financing (entremed.com) [edit]
Kleiner Perkins to Join $10.7M Financing for Publicly Held Biotech Co. EntreMed (pevc.dowjones.com) [edit]